ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA approves Grifols’ Xembify for immunodeficiencies pharmaceutical-technology
July 08, 2019Spanish plasma-derived medicine specialist Grifols has announced that the US Food and Drug Administration (FDA) has approved its Xembify (immune globulin subcutaneous, human- klhw) for patients over two years old with primary immunodeficiencies.
Pharma Sources Insight January 2025
